Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

irin.

  • Preclinical Data at EASL. On April 24, Anadys will present additional data on the preclinical profile of ANA598 at the EASL meeting in an oral presentation titled, "Preclinical Studies of ANA598 Combined with Other Anti-HCV Agents Demonstrate Potential of Combination Treatment." Anadys will present in vitro data showing that combinations of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that, through virtue of binding at a different site than ANA598, display a resistance profile distinct from that of ANA598. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir and PSI-6130.

ANA773

ANA773 is an oral prodrug of a small molecule inducer of endogenous interferons that acts via the toll-like receptor 7 (TLR7) pathway. Anadys has completed 3-month toxicology and pharmacology studies in animals that demonstrated stable induction of interferon-dependent pathways at doses that led to no adverse findings. Anadys is exploring ANA773 in chronic Hepatitis C and oncology.

  • Phase I Clinical Trial in HCV. Patient dosing in a Phase I clinical trial of ANA773 in HCV has been completed through 1600 mg dosed every other day (QOD). Based on the encouraging data we have seen to date, Anadys has submitted an amendment to this study to test ANA773 at 2000 mg QOD. In the completed cohorts, HCV patients received oral ANA773 or placebo every other day over 28 days, at doses of 800 mg, 1200 mg or 1600 mg, with six subjects receiving
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today announced that ... Apollo Light Systems, Inc., a 20-year-old, privately held ... for melatonin suppression and,circadian rhythm sleep disorders. Operating ... in American Fork, Utah and has annual revenues ...
... NKTR ) announced that Howard W. Robin, president ... upcoming BIO,InvestorForum at The Palace Hotel in San Francisco, ... Time. The presentation and Q&A session will be ... on the Investor Relations, Events,Calendar section of the Nektar ...
... from the Palace Hotel in San Francisco on Wednesday, October ... ... SAN DIEGO, Oct. 2 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... that Tamara,Seymour, Chief Financial Officer, will present at the Biotechnology,Industry Organization ...
Cached Biology Technology:Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/24/2014)...  Since its launch in December 2014, the 1U™ ... of trying to remember their usernames and passwords through replacing ... smartphones. To assist people who have struggled to remember usernames ... 1U and focuses on redefining identity, announced today that it ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... San Diego State University researchers will lead a study ... The Guizhou snub-nosed monkey, often called the golden monkey. ... the National Science Foundation, student researchers from SDSU,s departments ... month to the Fanjingshan National Nature Reserve, home to ...
... efficient cars, buildings and domestic appliances to address climate change ... Research at the University of East Anglia. A report ... as much effort is being spent on developing energy supply technologies ... improving the efficiency with which energy is used. The ...
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
Cached Biology News:SDSU researchers to study China's national treasure 2Efforts to mitigate climate change must target energy efficiency 2Efforts to mitigate climate change must target energy efficiency 3New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
Biology Products: